Abstract
Metastatic recurrence develops in 30%-40% of colorectal cancer (CRC) patients in the years that follow surgical removal of the primary tumor. In a recent issue of Nature, Cañellas-Socias etal. identify a distinct population of CRC cells, marked with epithelial membrane protein 1 (EMP1), accountable for metastatic relapse.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
